$CVS
CVS Health Corp

2024 Q3 Form 10-Q Financial Statement

#000006480324000029 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $91.23B
YoY Change 2.6%
Cost Of Revenue $50.00B
YoY Change -6.61%
Gross Profit $41.24B
YoY Change 16.54%
Gross Profit Margin 45.2%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.34B
YoY Change -67.34%
Operating Profit $3.045B
YoY Change -18.36%
Interest Expense -$732.0M
YoY Change 6.71%
% of Operating Profit -24.04%
Other Income/Expense, Net $24.00M
YoY Change 9.09%
Pretax Income $2.337B
YoY Change -9.07%
Income Tax $569.0M
% Of Pretax Income 24.35%
Net Earnings $1.770B
YoY Change -6.89%
Net Earnings / Revenue 1.94%
Basic Earnings Per Share $1.41
Diluted Earnings Per Share $1.41
COMMON SHARES
Basic Shares Outstanding 1.258B shares 1.255B shares
Diluted Shares Outstanding 1.259B shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.26B
YoY Change -3.7%
Cash & Equivalents $12.51B
Short-Term Investments $3.755B
Other Short-Term Assets $5.237B
YoY Change 29.89%
Inventory $16.07B
Prepaid Expenses
Receivables $32.39B
Other Receivables $4.634B
Total Short-Term Assets $69.95B
YoY Change 3.24%
LONG-TERM ASSETS
Property, Plant & Equipment $29.93B
YoY Change -2.51%
Goodwill $91.27B
YoY Change 0.01%
Intangibles $28.31B
YoY Change -6.0%
Long-Term Investments $25.03B
YoY Change 13.18%
Other Assets $4.798B
YoY Change -40.9%
Total Long-Term Assets $182.5B
YoY Change 0.12%
TOTAL ASSETS
Total Short-Term Assets $69.95B
Total Long-Term Assets $182.5B
Total Assets $252.5B
YoY Change 0.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $52.49B
YoY Change 14.65%
Accrued Expenses $21.16B
YoY Change -13.18%
Deferred Revenue $128.0M
YoY Change -20.5%
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due $3.731B
YoY Change 166.12%
Total Short-Term Liabilities $81.39B
YoY Change 2.75%
LONG-TERM LIABILITIES
Long-Term Debt $62.64B
YoY Change 1.99%
Other Long-Term Liabilities $5.526B
YoY Change -82.65%
Total Long-Term Liabilities $5.526B
YoY Change -94.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $81.39B
Total Long-Term Liabilities $5.526B
Total Liabilities $177.4B
YoY Change 0.01%
SHAREHOLDERS EQUITY
Retained Earnings $62.80B
YoY Change 6.67%
Common Stock $18.00M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.93B
YoY Change
Total Liabilities & Shareholders Equity $252.5B
YoY Change 0.96%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $1.770B
YoY Change -6.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $3.089B
YoY Change -47.71%
INVESTING ACTIVITIES
Capital Expenditures $638.0M
YoY Change 7.95%
Acquisitions
YoY Change
Other Investing Activities -$987.0M
YoY Change -89.9%
Cash From Investing Activities -$1.625B
YoY Change -84.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.249B
YoY Change -65.55%
NET CHANGE
Cash From Operating Activities 3.089B
Cash From Investing Activities -1.625B
Cash From Financing Activities 1.249B
Net Change In Cash 2.713B
YoY Change -427.66%
FREE CASH FLOW
Cash From Operating Activities $3.089B
Capital Expenditures $638.0M
Free Cash Flow $2.451B
YoY Change -53.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive,
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket,
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1257979270 shares
CY2024Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
30667000000 usd
CY2023Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
25108000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
61058000000 usd
us-gaap Premiums Earned Net
PremiumsEarnedNet
49460000000 usd
CY2024Q2 us-gaap Net Investment Income
NetInvestmentIncome
394000000 usd
CY2023Q2 us-gaap Net Investment Income
NetInvestmentIncome
274000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
848000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
608000000 usd
CY2023Q2 us-gaap Revenues
Revenues
88921000000 usd
us-gaap Revenues
Revenues
179671000000 usd
us-gaap Revenues
Revenues
174199000000 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
49998000000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
53536000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
98071000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
104991000000 usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
dei Document Type
DocumentType
10-Q
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
dei Entity File Number
EntityFileNumber
001-01011
us-gaap Profit Loss
ProfitLoss
2892000000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
9000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
19000000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1770000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1901000000 usd
us-gaap Interest Paid Net
InterestPaidNet
1131000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
729000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1779000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13346000000 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations
CY2024Q2 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations
CY2024Q2 us-gaap Revenues
Revenues
91234000000 usd
CY2024Q2 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
27853000000 usd
CY2023Q2 us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
21782000000 usd
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
55656000000 usd
us-gaap Policyholder Benefits And Claims Incurred Net
PolicyholderBenefitsAndClaimsIncurredNet
42230000000 usd
CY2024Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
10338000000 usd
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
9873000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
20628000000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
19453000000 usd
CY2024Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
88189000000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
85687000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
174355000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
167519000000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3045000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3234000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
5316000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6680000000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
732000000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
686000000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1448000000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1275000000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2337000000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2570000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3917000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5449000000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
569000000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.13
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1287000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1263000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.33
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.21
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
us-gaap Profit Loss
ProfitLoss
2892000000 usd
us-gaap Profit Loss
ProfitLoss
4056000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-27000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-64000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-135000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000000 usd
CY2024Q2 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
53000000 usd
CY2023Q2 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
60000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
121000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
-14000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
19000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-8000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
13000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
406000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1790000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1931000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2870000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
4462000000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
9000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1792000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1918000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2861000000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
656000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1025000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1393000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
us-gaap Profit Loss
ProfitLoss
4056000000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
us-gaap Net Income Loss
NetIncomeLoss
2883000000 usd
us-gaap Net Income Loss
NetIncomeLoss
4037000000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.13
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1287000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1263000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.33
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.21
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
us-gaap Profit Loss
ProfitLoss
2892000000 usd
us-gaap Profit Loss
ProfitLoss
4056000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-27000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-64000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-135000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000000 usd
CY2024Q2 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
53000000 usd
CY2023Q2 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
60000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
121000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
-14000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
19000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-8000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
13000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
406000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1790000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1931000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2870000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
4462000000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
13000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
9000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
19000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1792000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1918000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2861000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4443000000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12507000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8196000000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3755000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32385000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
16068000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
18025000000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5237000000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3151000000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
69952000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
67858000000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
25028000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13183000000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16901000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17252000000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
91272000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
91272000000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28311000000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29234000000 usd
CY2024Q2 us-gaap Separate Account Assets
SeparateAccountAssets
3187000000 usd
CY2023Q4 us-gaap Separate Account Assets
SeparateAccountAssets
3250000000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4798000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4660000000 usd
CY2024Q2 us-gaap Assets
Assets
252481000000 usd
CY2023Q4 us-gaap Assets
Assets
249728000000 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14416000000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14897000000 usd
CY2024Q2 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
24188000000 usd
CY2023Q4 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
22874000000 usd
CY2024Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
13885000000 usd
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2024Q2 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1051000000 usd
CY2023Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1326000000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21163000000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22189000000 usd
CY2024Q2 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1041000000 usd
CY2023Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1141000000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1911000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1741000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4443000000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12507000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8196000000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3755000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32385000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
16068000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
18025000000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5237000000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3151000000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
69952000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
67858000000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
25028000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13032000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
13183000000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16901000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17252000000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
91272000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
91272000000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28311000000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29234000000 usd
CY2024Q2 us-gaap Separate Account Assets
SeparateAccountAssets
3187000000 usd
CY2023Q4 us-gaap Separate Account Assets
SeparateAccountAssets
3250000000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4798000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4660000000 usd
CY2024Q2 us-gaap Assets
Assets
252481000000 usd
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14416000000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14897000000 usd
CY2024Q2 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
24188000000 usd
CY2023Q4 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
22874000000 usd
CY2024Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
13885000000 usd
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2024Q2 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1051000000 usd
CY2023Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1326000000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21163000000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22189000000 usd
CY2024Q2 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1041000000 usd
CY2023Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1141000000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1911000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1741000000 usd
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
0 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
200000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3731000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
81386000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
79189000000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15537000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16034000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
62643000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
0 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
200000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3731000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
81386000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
79189000000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15537000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16034000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
62643000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4052000000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4311000000 usd
CY2024Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3187000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2024Q2 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5039000000 usd
CY2023Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5459000000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5526000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6211000000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
177370000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
173092000000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1777000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1256000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1768000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1288000000 shares
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
49371000000 usd
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48992000000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
521000000 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
480000000 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
36919000000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
33838000000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
62797000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
61604000000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-319000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-297000000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
74930000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
76461000000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
181000000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
175000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75111000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252481000000 usd
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4052000000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4311000000 usd
CY2024Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3187000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2024Q2 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5039000000 usd
CY2023Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5459000000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5526000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6211000000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
177370000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
173092000000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1777000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1256000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1768000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1288000000 shares
CY2024Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
49371000000 usd
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48992000000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
521000000 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
480000000 shares
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
36919000000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
33838000000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
62797000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
61604000000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-319000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-297000000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
74930000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
76461000000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
181000000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
175000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75111000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252481000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
249728000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
173728000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
175567000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
90845000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
101318000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
52485000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
41108000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
17686000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
249728000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
173728000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
175567000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
90845000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
52485000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
41108000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
21124000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
17686000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
839000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
801000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7992000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4418000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3640000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6781000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4499000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1343000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1575000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
73000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16474000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-60000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-32000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3719000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18876000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
-200000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
1000000000 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
5000000000 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
0 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
5000000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4959000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10898000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
37000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1787000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3024000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2016000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1698000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1574000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
228000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
120000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
176000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
168000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-30000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-121000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6352000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4295000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
822000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13305000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12820000000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14127000000 usd
us-gaap Profit Loss
ProfitLoss
2892000000 usd
us-gaap Profit Loss
ProfitLoss
4056000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2289000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2105000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
801000000 usd
us-gaap Interest Paid Net
InterestPaidNet
1392000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7992000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4418000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3640000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6781000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4499000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1575000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
73000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16474000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-60000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-32000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3719000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18876000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
-200000000 usd
us-gaap Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
1000000000 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
5000000000 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
0 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
5000000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4959000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10898000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
37000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1787000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3024000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2016000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1698000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1574000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
228000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
120000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
176000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
168000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-121000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6352000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4295000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
822000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12820000000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14127000000 usd
us-gaap Profit Loss
ProfitLoss
2892000000 usd
us-gaap Profit Loss
ProfitLoss
4056000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2289000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
270000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
307000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
-341000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
87000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2798000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
804000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1937000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1800000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2241000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
913000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1191000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-118000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
270000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
307000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
-341000000 usd
cvs Deferred Income Taxes And Other Items
DeferredIncomeTaxesAndOtherItems
87000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2798000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
804000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1937000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1800000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2241000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
913000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1191000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-118000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
1581000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4334000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2384000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2492000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7992000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13346000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
1124000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-44000000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000000 usd
CY2024Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
2962000000 usd
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
844000000 usd
CY2024Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-4000000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74150000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
159000000 usd
CY2024Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
143000000 usd
CY2024Q2 us-gaap Dividends Common Stock
DividendsCommonStock
846000000 usd
CY2024Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
1000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75111000000 usd
CY2023Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2024Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
2142000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
389000000 usd
CY2023Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-99000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71580000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000000 usd
CY2023Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
129000000 usd
CY2023Q2 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q2 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
66000000 usd
CY2023Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-5000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
1581000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4334000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2384000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2492000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7992000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13346000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76636000000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
1124000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-44000000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000000 usd
CY2024Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
2962000000 usd
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
844000000 usd
CY2024Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-4000000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74150000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1768000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
159000000 usd
CY2024Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
143000000 usd
CY2024Q2 us-gaap Dividends Common Stock
DividendsCommonStock
846000000 usd
CY2024Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
1000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75111000000 usd
CY2023Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2024Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2024Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
2142000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
389000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
122000000 usd
CY2023Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
1962000000 usd
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
781000000 usd
CY2023Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-99000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71580000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000000 usd
CY2023Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
129000000 usd
CY2023Q2 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q2 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
66000000 usd
CY2023Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-5000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73002000000 usd
CY2023Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73002000000 usd
CY2023Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q2 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
90000000 people
CY2024Q2 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
800000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2023 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12507000000 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2024Q2 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
90000000 people
CY2024Q2 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
800000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
CY2023 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12507000000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
259000000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
239000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12820000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8196000000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000000 usd
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
259000000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
239000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12820000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8525000000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9793000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q2 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
13528000000 usd
CY2023Q4 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
15711000000 usd
CY2024Q2 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
4430000000 usd
CY2023Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3714000000 usd
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4634000000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3894000000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32385000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
355000000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
343000000 usd
CY2023Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1502000000 usd
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1219000000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9793000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q2 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
13528000000 usd
CY2023Q4 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
15711000000 usd
CY2024Q2 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
4430000000 usd
CY2023Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3714000000 usd
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4634000000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3894000000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32385000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35227000000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
355000000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
343000000 usd
CY2023Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1502000000 usd
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1219000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
271000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
274000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
146000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
128000000 usd
CY2024Q2 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1627000000 usd
CY2023Q2 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1365000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
271000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
274000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
146000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
128000000 usd
CY2024Q2 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1627000000 usd
CY2023Q2 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1365000000 usd
CY2024Q2 us-gaap Net Investment Income
NetInvestmentIncome
394000000 usd
CY2024Q2 us-gaap Revenues
Revenues
91234000000 usd
CY2023Q2 us-gaap Net Investment Income
NetInvestmentIncome
274000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
848000000 usd
us-gaap Revenues
Revenues
179671000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
608000000 usd
us-gaap Revenues
Revenues
174199000000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9793000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
128000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
149000000 usd
CY2024Q2 us-gaap Net Investment Income
NetInvestmentIncome
394000000 usd
CY2024Q2 us-gaap Revenues
Revenues
91234000000 usd
CY2023Q2 us-gaap Net Investment Income
NetInvestmentIncome
274000000 usd
CY2023Q2 us-gaap Revenues
Revenues
88921000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
848000000 usd
us-gaap Revenues
Revenues
179671000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
608000000 usd
us-gaap Revenues
Revenues
174199000000 usd
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9793000000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
11908000000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
128000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
149000000 usd
CY2023Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2023Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3755000000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
25028000000 usd
CY2024Q2 us-gaap Investments
Investments
28783000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2023Q4 us-gaap Investments
Investments
26278000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
24548000000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
146000000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
863000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23831000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22282000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
267000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
836000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21713000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1365000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1349000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
8974000000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3755000000 usd
CY2024Q2 us-gaap Long Term Investments
LongTermInvestments
25028000000 usd
CY2024Q2 us-gaap Investments
Investments
28783000000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3259000000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
23019000000 usd
CY2023Q4 us-gaap Investments
Investments
26278000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
24548000000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
146000000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
863000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23831000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22282000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
267000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
836000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21713000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1349000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
8974000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8784000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4420000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4288000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
3560000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3310000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
24548000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23831000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
3497 security
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6042000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
64000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
6232 security
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
8959000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
799000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
9729 security
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8784000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4420000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4288000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
3560000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3310000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
24548000000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23831000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
3497 security
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6042000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
64000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
6232 security
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
8959000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
799000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
9729 security
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15001000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
863000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1182 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1932000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
28000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
7018 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10616000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
808000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8200 security
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
12548000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
836000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
1128000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
17000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
223000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
2698000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
171000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
2368000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
287000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15001000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
863000000 usd
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
496000000 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
383000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
980000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
832000000 usd
CY2024Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
12000000 usd
CY2023Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
24000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
21000000 usd
CY2024Q2 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
484000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15001000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
863000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1182 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1932000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
28000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
7018 security
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10616000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
808000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8200 security
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
12548000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
836000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
1128000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
17000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
6308000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
223000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
2698000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
171000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
2368000000 usd
CY2024Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
287000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15001000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
863000000 usd
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
496000000 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
383000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
980000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
832000000 usd
CY2024Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
12000000 usd
CY2023Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
24000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
21000000 usd
CY2024Q2 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
484000000 usd
CY2023Q2 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
372000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
956000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
811000000 usd
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-90000000 usd
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-98000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-108000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-203000000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
394000000 usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
274000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
848000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
608000000 usd
CY2024Q2 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
28000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
38000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
956000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
811000000 usd
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-90000000 usd
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-98000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-108000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-203000000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
394000000 usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
274000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
848000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
608000000 usd
CY2024Q2 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
28000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
38000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2024Q2 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2023Q2 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
37000000 usd
CY2023Q2 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-2000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
61000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-3000000 usd
CY2024Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1616000000 usd
CY2023Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
991000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2881000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2332000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
2000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
14000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
5000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
71000000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
73000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
123000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
184000000 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
13000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
42000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the six months ended June 30, 2024 and 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,015 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,998 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span>Total incurred health care costs for the six months ended June 30, 2024 and 2023 in the table above exclude $48 million and $42 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $93 million and $102 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2023Q4 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
5000000 usd
CY2023Q4 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
23000000 usd
CY2023Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12067000000 usd
CY2024Q2 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
CY2023Q2 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
37000000 usd
CY2023Q2 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-2000000 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
61000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-3000000 usd
CY2024Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1616000000 usd
CY2023Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
991000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2881000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2332000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
2000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
14000000 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
5000000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
71000000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
73000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
123000000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
184000000 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
42000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the six months ended June 30, 2024 and 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,015 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,998 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span>Total incurred health care costs for the six months ended June 30, 2024 and 2023 in the table above exclude $48 million and $42 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $93 million and $102 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
CY2023Q4 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
12049000000 usd
CY2023Q4 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
5000000 usd
CY2023Q4 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
23000000 usd
CY2023Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12067000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
0 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
56177000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
42705000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-662000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-619000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
55515000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
42086000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
43218000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
32502000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
10514000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
8800000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
53732000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
41302000000 usd
CY2024Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
13850000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
0 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
1102000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
56177000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
42705000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-662000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-619000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
55515000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
42086000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
43218000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
32502000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
10514000000 usd
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
8800000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
53732000000 usd
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
41302000000 usd
CY2024Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
13850000000 usd
CY2023Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12015000000 usd
CY2024Q2 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
59000000 usd
CY2023Q2 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
5000000 usd
CY2024Q2 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
24000000 usd
CY2023Q2 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
22000000 usd
CY2024Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
13885000000 usd
CY2023Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
11998000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-662000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-619000000 usd
CY2024Q2 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
10600000000 usd
CY2023Q4 us-gaap Policyholder Funds
PolicyholderFunds
332000000 usd
CY2022Q4 us-gaap Policyholder Funds
PolicyholderFunds
345000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
8000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
-1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
7000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
20000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
6000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
5000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
-12000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
16000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-13000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-14000000 usd
CY2024Q2 us-gaap Policyholder Funds
PolicyholderFunds
313000000 usd
CY2023Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
12015000000 usd
CY2024Q2 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
59000000 usd
CY2023Q2 us-gaap Reinsurance Recoverable For Unpaid Claims And Claims Adjustments
ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
5000000 usd
CY2024Q2 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
24000000 usd
CY2023Q2 us-gaap Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax
AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax
22000000 usd
CY2024Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
13885000000 usd
CY2023Q2 cvs Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor
LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor
11998000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-662000000 usd
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-619000000 usd
CY2024Q2 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
10600000000 usd
CY2023Q4 us-gaap Policyholder Funds
PolicyholderFunds
332000000 usd
CY2022Q4 us-gaap Policyholder Funds
PolicyholderFunds
345000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
8000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
-1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
7000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
20000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
6000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
5000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
-12000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-13000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-14000000 usd
CY2024Q2 us-gaap Policyholder Funds
PolicyholderFunds
313000000 usd
CY2023Q2 us-gaap Policyholder Funds
PolicyholderFunds
330000000 usd
CY2024Q2 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0435
CY2023Q2 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0455
CY2024Q2 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2023Q2 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2024Q2 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
317000000 usd
CY2023Q2 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
323000000 usd
CY2023Q2 us-gaap Policyholder Funds
PolicyholderFunds
330000000 usd
CY2024Q2 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0435
CY2023Q2 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0455
CY2024Q2 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2023Q2 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2024Q2 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
317000000 usd
CY2023Q2 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
323000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2022Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3228000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
430000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
152000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
6000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
449000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
495000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
121000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
88000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-4000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-2000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-17000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-7000000 usd
CY2024Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3187000000 usd
CY2023Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3267000000 usd
CY2024Q2 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2171000000 usd
CY2023Q2 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2152000000 usd
CY2024Q2 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1379000000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1391000000 usd
CY2024Q2 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
66944000000 usd
CY2023Q4 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
62160000000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
178000000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
186000000 usd
CY2024Q2 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
748000000 usd
CY2023Q4 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
736000000 usd
CY2024Q2 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
66374000000 usd
CY2023Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
61610000000 usd
CY2024Q2 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3731000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
62643000000 usd
CY2023Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3250000000 usd
CY2022Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3228000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
430000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
457000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
152000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
6000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
449000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
495000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
121000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
88000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-4000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-2000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-17000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-7000000 usd
CY2024Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3187000000 usd
CY2023Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3267000000 usd
CY2024Q2 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2171000000 usd
CY2023Q2 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2152000000 usd
CY2024Q2 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1379000000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1391000000 usd
CY2024Q2 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
66944000000 usd
CY2023Q4 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
62160000000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
178000000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
186000000 usd
CY2024Q2 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
748000000 usd
CY2023Q4 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
736000000 usd
CY2024Q2 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
66374000000 usd
CY2023Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
61610000000 usd
CY2024Q2 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2023Q4 us-gaap Commercial Paper
CommercialPaper
200000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3731000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2772000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
62643000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
58638000000 usd
CY2024Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.21
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
406000000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1770000000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1770000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1901000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1901000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2883000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2883000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4037000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4037000000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1287000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1263000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.665
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.33
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.21
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
406000000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1770000000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1770000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1901000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1901000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2883000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4037000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4037000000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1256000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1258000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1283000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1259000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1287000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1263000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.41
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.13
CY2024Q2 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
62 lease
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.13
CY2024Q2 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
62 lease
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2024Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
90840000000 usd
CY2024Q2 us-gaap Net Investment Income
NetInvestmentIncome
394000000 usd
CY2024Q2 us-gaap Revenues
Revenues
91234000000 usd
CY2024Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3744000000 usd
CY2023Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
88647000000 usd
CY2023Q2 us-gaap Net Investment Income
NetInvestmentIncome
274000000 usd
CY2023Q2 us-gaap Revenues
Revenues
88921000000 usd
CY2023Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4481000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
178823000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
848000000 usd
us-gaap Revenues
Revenues
179671000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
6701000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
173591000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
608000000 usd
us-gaap Revenues
Revenues
174199000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
8851000000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3045000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3234000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
5316000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6680000000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
507000000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
485000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1015000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
887000000 usd
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-90000000 usd
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-98000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-108000000 usd
CY2024Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
102000000 usd
CY2023Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
157000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
162000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
200000000 usd
CY2024Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-100000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2024Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
CY2024Q2 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
CY2023Q2 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
11000000 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
36000000 usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2024Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
90840000000 usd
CY2024Q2 us-gaap Net Investment Income
NetInvestmentIncome
394000000 usd
CY2024Q2 us-gaap Revenues
Revenues
91234000000 usd
CY2024Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3744000000 usd
CY2023Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
88647000000 usd
CY2023Q2 us-gaap Net Investment Income
NetInvestmentIncome
274000000 usd
CY2023Q2 us-gaap Revenues
Revenues
88921000000 usd
CY2023Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4481000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
178823000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
848000000 usd
us-gaap Revenues
Revenues
179671000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
6701000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
173591000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
608000000 usd
us-gaap Revenues
Revenues
174199000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
8851000000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3045000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3234000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
5316000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6680000000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
507000000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
485000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1015000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
887000000 usd
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-90000000 usd
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-98000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-108000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-203000000 usd
CY2024Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
102000000 usd
CY2023Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
157000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
162000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
200000000 usd
CY2024Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2023Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-100000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2024Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
CY2024Q2 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
CY2023Q2 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
11000000 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
36000000 usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2023Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
CY2024Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3744000000 usd
CY2023Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4481000000 usd
CY2024Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3744000000 usd
CY2023Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4481000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
6701000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
8851000000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
6701000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
8851000000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000064803-24-000029-index-headers.html Edgar Link pending
0000064803-24-000029-index.html Edgar Link pending
0000064803-24-000029.txt Edgar Link pending
0000064803-24-000029-xbrl.zip Edgar Link pending
a06302024ex101.htm Edgar Link pending
a06302024ex102.htm Edgar Link pending
a06302024ex103.htm Edgar Link pending
a06302024ex151.htm Edgar Link pending
a06302024ex311.htm Edgar Link pending
a06302024ex312.htm Edgar Link pending
a06302024ex321.htm Edgar Link pending
a06302024ex322.htm Edgar Link pending
cvs-20240630.htm Edgar Link pending
cvs-20240630.xsd Edgar Link pending
cvs-20240630_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
cvs-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cvs-20240630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvs-20240630_def.xml Edgar Link unprocessable
cvs-20240630_pre.xml Edgar Link unprocessable
cvs-20240630_cal.xml Edgar Link unprocessable